Search

Wei Zhu

from Rockville, MD
Get Report
Also known as:
Wei Z Hu
Related to:
Vince F Chen, 71Chang Qiang ZhuMu Q Chen, 50Huan R Chen, 49Alex Q Zhu, 42Guo C Zhu, 67Min R Chen, 49Yufeng ZhuShan Zhu, 49Penghua Zhu, 48Hexiang Zhu, 58Zhuang L Chen, 52Wen Tan, 61
Connected to:
Ailin Zhu, 37Anne Q Zhu, 57Annie L Zhu, 71Athena Zhu, 32Banghe Zhu, 52Beck Zhu, 62Ben S Zhu, 56Bessie Zhu, 37Bijun Zhu, 33Bing Q Zhu, 44

Wei Zhu Phones & Addresses

  • Rockville, MD
  • Clinton, MD

Publications

Amazon

Vacuum Microelectronics

View page

Expert coverage of vacuum microelectronics-principles, devices, and applications The field of vacuum microelectronics has advanced so swiftly that commercial devices are being fabricated, and applications are being developed in displays, wireless communications, spacecraft, and electronics for use i...
Binding

Hardcover

Pages

408

Publisher

Wiley-Interscience

ISBN #

047132244X

EAN Code

9780471322443

ISBN #

4

The magic of thinking big(Chinese Edition)

View page
Author

(MEI )DA WEI ? SHU WA CI ZHU LAI WEI XIONG YI

Binding

Paperback

Publisher

big magical thinking World Knowledge Press.

ISBN #

7501234493

EAN Code

9787501234493

ISBN #

1

Sub-health caused by spinal cord injury--- Chinese Traditinal Medicine Therapy (Chinese Edition)

View page

It advocates a new concept of sub-health caused by spinal cord injury, giving a brief introduction of the sub-health. As a leading authority in the field of spinal cord, the author introduced a systematic treatment of acupuncture and acupressure, as well as recuperation of traditional Chinese medici...
Author

gao wei zhu

Binding

Paperback

Pages

432

Publisher

Guangxi Normal University Press

ISBN #

7563397868

EAN Code

9787563397860

ISBN #

9

Language Learning and Teaching as Social Interaction

View page

This volume brings together contributions by leading researchers active in developing the social interactional and socio-cultural approaches to language learning and teaching. It provides not only an introduction to this important growth point, but also an overview of cutting edge research, covering...
Binding

Hardcover

Pages

320

Publisher

Palgrave Macmillan

ISBN #

0230517005

EAN Code

9780230517004

ISBN #

5

English-Chinese Simultaneous Interpretation

View page

The Chinese Ministry of Education approved in 2005 to set translation majors for undergraduates, providing a new opportunity for the construction and development of translation disciplines. This book is written on the basis of extensive research to suppor
Author

zhang wei wei bian zhu

Binding

Paperback

Pages

225

Publisher

Shanghai Foreign Language Education Press

ISBN #

7544620670

EAN Code

9787544620673

ISBN #

7

Handbook on Classroom Skills for International Chinese Teachers (Chinese Edition)

View page

The book applies to the international Chinese teachers, volunteer teachers, undergraduate and graduate students who major in International Chinese Education. It can be used in teaching International Chinese Education as the major area, vocational training
Author

wang wei deng zhu

Binding

Paperback

Pages

262

Publisher

Higher Education Press

ISBN #

7040306549

EAN Code

9787040306545

ISBN #

3

CAI GUOQIANG: WHAT I AM THINKING ABOUT (Chinese Edition)

View page

This book is the first and comprehensive introduction of artist Cai Guoqiang , except the independent but not lonely road of searching for art, it also a coreduction of him to be a husband and a father.
Author

Yang Zhao. Li Wei Jing. Zhu

Binding

Paperback

Pages

345

Publisher

Guangxi Normal University Press

ISBN #

756339818X

EAN Code

9787563398188

ISBN #

10

Isbn (Books And Publications)

Vacuum Microelectronics

View page
Author

Wei Zhu

ISBN #

0471224332

Vacuum Microelectronics

View page
Author

Wei Zhu

ISBN #

0471464090

Us Patents

Type 1 Inteferon Diagnostic

View page
US Patent:
20120251546, Oct 4, 2012
Filed:
Sep 2, 2010
Appl. No.:
13/393616
Inventors:
Brandon Higgs - Gaithersburg MD, US
Wei Zhu - Boyds MD, US
Chris Morehouse - Middletown MD, US
Barbara White - Finksburg MD, US
Bahija Jallal - Potomac MD, US
Yihong Yao - Boyds MD, US
Assignee:
MEDIMMUNE LLC - GAITHERBURG MD
International Classification:
A61K 39/395
G06F 19/00
G01N 21/64
US Classification:
4241421, 435 611, 4241581, 4241721, 702 19
Abstract:
The present disclosure encompasses type-I IFN and IFNα-induced PD marker expression profiles, kits, and methods for identifying such IFNα-induced PD marker expression profiles. The type-I IFN and IFNα-induced PD marker expression profiles may also be used in, for example, methods of treating patients having a type-I IFN or IFNα-mediated disorder, methods of monitoring disease progression of patients receiving treatment with a therapeutic agent that modulates type 1 interferon activity, identifying patients as candidates to receive a therapeutic that binds to and neutralizes IFNα activity, and in diagnosing or providing a prognosis to patients having IFNα-induced disorders.

Optimized Degenerative Muscle Disease Diagnostics And Treatments

View page
US Patent:
20130108646, May 2, 2013
Filed:
May 4, 2011
Appl. No.:
13/695714
Inventors:
Yihong Yao - Boyds MD, US
Robert William Georgantas - Gaithersburg MD, US
Wei Zhu - Boyds MD, US
Katie Streicher - Bethesda MD, US
Koustubh Ranade - Potomac MD, US
Assignee:
MEDIMMUNE, LLC - Gaithersburg MD
International Classification:
A61K 39/395
A61K 45/00
A61K 39/00
A61K 31/56
A61K 35/34
A61K 31/7088
US Classification:
4241581, 435377, 424 937, 514 44 A, 4241841, 514169, 435 29, 435 61
Abstract:
Provided herein are optimized methods for treating a degenerative muscle disease, which comprise determining the presence, absence or amount of a biomarker associated with the disease after a drug has been administered, and determining whether a subsequent dose of the drug should be maintained, increased or decreased based on the biomarker assessment. Increased levels of certain biomarkers are linked to muscle degenerative diseases (e.g., GM-CSF(CSF2), TNF-alpha or other pro-inflammatory cytokine acting through NF kappa B), and decreased levels of certain biomarkers are linked to the muscle degenerative diseases 9 e.g., particular microRNA (e.g., miRNA-1, miRNA-133, miRNA-206)). Such methods optimize therapeutic efficacy and minimize toxicity associated with a drug. Also provided herein are therapeutics for treating muscle disorders.

Melanoma Treatments

View page
US Patent:
20140045924, Feb 13, 2014
Filed:
Dec 14, 2011
Appl. No.:
13/994291
Inventors:
Yihong Yao - Boyds MD, US
Katie Streicher - Bethesda MD, US
Wei Zhu - Boyds MD, US
Koustubh Ranade - Potomac MD, US
Assignee:
MEDIMMUNE, LLC - Gaithersburg MD
International Classification:
C12N 15/113
US Classification:
514 44 R, 536 231
Abstract:
Provided herein, in some embodiments, are methods for treating melanoma, improving therapeutic effectiveness of drugs and reducing drug toxicity.

Construction Of Chimeric Antigen Receptor Targeting Cd20 Antigen And Activity Identification Of Engineered T Cells Thereof

View page
US Patent:
20220340640, Oct 27, 2022
Filed:
Jun 3, 2022
Appl. No.:
17/831637
Inventors:
- Hong kong, CN
Jiaqi HUANG - Rockville MD, US
Shigui ZHU - Rockville MD, US
Wei ZHU - Rockville MD, US
Xin YAO - Rockville MD, US
Zhiyuan LI - Hong Kong, CN
Li ZHANG - Rockville MD, US
Lin ZHU - Hong Kong, CN
Anyun MA - Hong Kong, CN
Yutian WEI - Hong Kong, CN
Yanfeng LI - Hong Kong, CN
Qingxia WANG - Hong Kong, CN
Jiaping HE - Hong Kong, CN
International Classification:
C07K 14/725
A61P 35/00
A61K 35/17
C07K 14/705
C07K 16/28
C12N 7/00
C12N 15/86
C07K 19/00
C12N 5/10
C12N 15/62
A61P 35/02
A61K 9/00
Abstract:
Provided are a chimeric antigen receptor targeting CD20 antigen and a preparation method thereof. The extracellular antigen binding domain of the chimeric antigen receptor includes an antibody heavy chain variable region shown in SEQ ID NO: 7 or 9 or 33 and an antibody light chain variable region shown in SEQ ID NO: 11 or 13 or 35, and is capable of killing tumor cells.

Construction Of Chimeric Antigen Receptor Targeting Cd20 Antigen And Activity Identification Of Engineered T Cells Thereof

View page
US Patent:
20220324940, Oct 13, 2022
Filed:
Apr 19, 2022
Appl. No.:
17/723859
Inventors:
- Hong Kong, CN
Jiaqi HUANG - Rockville MD, US
Shigui ZHU - Rockville MD, US
Wei ZHU - Rockville MD, US
Xin YAO - Rockville MD, US
Zhiyuan LI - Hong Kong, CN
Li ZHANG - Rockville MD, US
Lin ZHU - Hong Kong, CN
Anyun MA - Hong Kong, CN
Yutian WEI - Hong Kong, CN
Yanfeng LI - Hong Kong, CN
Qingxia WANG - Hong Kong, CN
Jiaping HE - Hong Kong, CN
International Classification:
C07K 14/725
A61P 35/00
A61K 35/17
C07K 14/705
C07K 16/28
C12N 7/00
C12N 15/86
C07K 19/00
C12N 5/10
C12N 15/62
A61P 35/02
A61K 9/00
Abstract:
Provided are a chimeric antigen receptor targeting CD20 antigen and a preparation method thereof. The extracellular antigen binding domain of the chimeric antigen receptor includes an antibody heavy chain variable region shown in SEQ ID NO: 7 or 9 or 33 and an antibody light chain variable region shown in SEQ ID NO: 11 or 13 or 35, and is capable of killing tumor cells.

Construction Of Chimeric Antigen Receptor Targeting Cd20 Antigen And Activity Identification Of Engineered T Cells Thereof

View page
US Patent:
20220281945, Sep 8, 2022
Filed:
May 23, 2022
Appl. No.:
17/750855
Inventors:
- Hong Kong, CN
Jiaqi HUANG - Rockville MD, US
Shigui ZHU - Rockville MD, US
Wei ZHU - Rockville MD, US
Xin YAO - Rockville MD, US
Zhiyuan LI - Hong Kong, CN
Li ZHANG - Rockville MD, US
Lin ZHU - Hong Kong, CN
Anyun MA - Hong Kong, CN
Yutian WEI - Hong Kong, CN
Yanfeng LI - Hong Kong, CN
Qingxia WANG - Hong Kong, CN
Jiaping HE - Hong Kong, CN
International Classification:
C07K 14/725
A61P 35/00
A61K 35/17
C07K 14/705
C07K 16/28
C12N 7/00
C12N 15/86
C07K 19/00
C12N 5/10
C12N 15/62
A61P 35/02
A61K 9/00
Abstract:
Provided are a chimeric antigen receptor targeting CD20 antigen and a preparation method thereof. The extracellular antigen binding domain of the chimeric antigen receptor includes an antibody heavy chain variable region shown in SEQ ID NO: 7 or 9 or 33 and an antibody light chain variable region shown in SEQ ID NO: 11 or 13 or 35, and is capable of killing tumor cells.

Biocompatible Smart Biomaterials With Tunable Shape Changing And Enhanced Cytocompatibility Properties

View page
US Patent:
20200237963, Jul 30, 2020
Filed:
Aug 25, 2016
Appl. No.:
15/754938
Inventors:
- Washington DC, US
Wei Zhu - Washington DC, US
Nathan J. Castro - Washington DC, US
Lijie G. Zhang - Arlington VA, US
Assignee:
The George Washington University a Congressionally Chartered Not-for-Profit Corporation - Washington DC
International Classification:
A61L 27/50
A61L 27/56
A61L 27/36
A61L 27/18
Abstract:
The present application relates to biocompatible polymers that exhibit a shape-memory effect, devices made using the materials and methods of producing such materials and devices.

Vascularized Biphasic Tissue Constructs

View page
US Patent:
20190030212, Jan 31, 2019
Filed:
Mar 20, 2018
Appl. No.:
15/926679
Inventors:
- Washington DC, US
Haitao Cui - Arlington VA, US
Wei Zhu - Washington DC, US
International Classification:
A61L 27/54
A61F 2/28
A61F 2/30
A61L 27/26
A61L 27/18
A61L 27/34
A61L 27/52
A61K 35/51
A61K 35/28
A61K 38/18
A61L 27/38
B33Y 10/00
B33Y 70/00
B33Y 80/00
Abstract:
Biphasic tissue constructs that include a scaffold having one or more channels, a vascular portion comprising a hydrogel at least partially disposed in the one or more channels, and a first bioactive growth factor and a second bioactive growth factor different from the first bioactive growth factor, the first bioactive growth factor localized to the scaffold and the second bioactive growth factor localized to the vascular portion. The first bioactive growth factor may be bone morphogenetic protein 2 (BMP2) peptide and the second bioactive growth factor may be vascular endothelial growth factor (VEGF) peptide.
Control profile
Wei Zhu from Rockville, MD Get Report